Baloxavir Marboxil
Other Antivirals
Sold as Xofluza
- Drug class
- Other Antivirals
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 7
Overview
Baloxavir Marboxil is an active pharmaceutical ingredient in the Other Antivirals group (J05AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 29, 2026 |
| EU European Union | EMA | 1 | May 20, 2026 |
| CA Canada | Health Canada | 3 | February 9, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Treatment of influenza Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 3 weeks and above. Post-exposure prophylaxis of influenza Xofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.
Xofluza should be used in accordance with official recommendations.
How to take
EUEuropean Union· EMA
1 product
Uses
Treatment of influenza Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 3 weeks and above. Post-exposure prophylaxis of influenza Xofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.
Xofluza should be used in accordance with official recommendations.
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Baloxavir Marboxil. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000310926 · revised May 29, 2026
- [2]European Medicines Agency · EMEA/H/C/004974 · revised May 20, 2026
- [3]Health Canada (DPD) · 02496364 · revised October 3, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.